Evidence map›Paper›PMID 40236508›Full record

ArticleAmerican journal of ophthalmology case reports2025

Netarsudil-associated conjunctival pigmentation.

Soufiane Azargui, Joana Karanxha, Scott Cn Oliver, Malik Y Kahook, Cara E Capitena Young

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Netarsudil-associated conjunctival fragility.American journal of ophthalmology case reports · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Soufiane AzarguiDepartment of Ophthalmology, University of Colorado School of Medicine, Sue Anschutz-Rodgers Eye Center, Aurora, Colorado, USA.
Joana KaranxhaDepartment of Ophthalmology, University of Colorado School of Medicine, Sue Anschutz-Rodgers Eye Center, Aurora, Colorado, USA.
Scott Cn OliverDepartment of Ophthalmology, University of Colorado School of Medicine, Sue Anschutz-Rodgers Eye Center, Aurora, Colorado, USA.
Malik Y KahookDepartment of Ophthalmology, University of Colorado School of Medicine, Sue Anschutz-Rodgers Eye Center, Aurora, Colorado, USA.
Cara E Capitena YoungDepartment of Ophthalmology, University of Colorado School of Medicine, Sue Anschutz-Rodgers Eye Center, Aurora, Colorado, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To present a case of conjunctival pigmentation associated with topical use of netarsudil 0.02 % (Rhopressa, Alcon, Fort Worth, TX). Observation: Bilateral conjunctival pigmentation and cornea verticillata developed after 21 months of initiating netarsudil treatment. The appearance of the conjunctival pigmentation mimicked primary acquired melanosis. Both the conjunctival and corneal findings resolved 14 months after stopping the medication. Conclusion: While the correlation between netarsudil use and corneal verticillata is well-established, we could not identify prior reports of such an association with conjunctival pigmentation. Eye care professionals prescribing netarsudil should be aware of this potential sequela of therapy.

Indexed as

Conjunctival pigmentationNetarsudilPrimary acquired melanosisRhopressa

Identifiers

PMID40236508
PMCPMC11998109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.